Reuters logo
BRIEF-Otonomy reports positive results from averts-2 phase 3 trial of otividex™ in patients with ménière's disease
November 8, 2017 / 9:31 PM / 11 days ago

BRIEF-Otonomy reports positive results from averts-2 phase 3 trial of otividex™ in patients with ménière's disease

Nov 8 (Reuters) - Otonomy Inc

* Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière’s disease

* Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière’s disease

* Otonomy Inc - ‍achieved primary endpoint in study​

* Otonomy Inc - ‍company plans to meet with FDA to discuss results of study and clinical requirements for registration​

* Otonomy Inc - ‍otividex was generally well-tolerated with no drug-related serious adverse events observed​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below